GLX351322
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555343

CAS#: 835598-94-2

Description: GLX351322 is a NADPH oxidase 4 inhibitor. GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. GLX351322 inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells with IC50 of 5 uM.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 2950
Size
Price

25mg
USD 250
200mg
USD 1250
2g
USD 4250
Size
Price

50mg
USD 450
500mg
USD 1950
5g
USD 6550

GLX351322, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 700 mg may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555343
Name: GLX351322
CAS#: 835598-94-2
Chemical Formula: C21H25N3O5S
Exact Mass: 431.1515
Molecular Weight: 431.51
Elemental Analysis: C, 58.45; H, 5.84; N, 9.74; O, 18.54; S, 7.43


Synonym: GLX351322; GLX-351322; GLX 351322

IUPAC/Chemical Name: Ethyl 2-[[2-[4-(furan-2-carbonyl)piperazin-1-yl]acetyl]amino]-5,6-dihydro-4H-cyclopenta-[b]thiophene-3-carboxylate

InChi Key: KEVHLTCEMHIJTQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H25N3O5S/c1-2-28-21(27)18-14-5-3-7-16(14)30-19(18)22-17(25)13-23-8-10-24(11-9-23)20(26)15-6-4-12-29-15/h4,6,12H,2-3,5,7-11,13H2,1H3,(H,22,25)

SMILES Code: O=C(C1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)SC4=C1CCC4)OCC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


Additional Information

In type 2 diabetes, it has been proposed that pancreatic beta-cell dysfunction is promoted by oxidative stress caused by NADPH oxidase (NOX) overactivity. Five different NOX enzymes (NOX1-5) have been characterized, among which NOX1 and NOX2 have been proposed to negatively affect beta-cells, but the putative role of NOX4 in type 2 diabetes-associated beta-cell dysfunction and glucose intolerance is largely unknown


References

1: Wang X, Elksnis A, Wikström P, Walum E, Welsh N, Carlsson PO. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro. PLoS One. 2018 Sep 28;13(9):e0204271. doi: 10.1371/journal.pone.0204271. eCollection 2018. PubMed PMID: 30265686; PubMed Central PMCID: PMC6161897.

2: Anvari E, Wikström P, Walum E, Welsh N. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18. doi: 10.3109/10715762.2015.1067697. Epub 2015 Jul 30. PubMed PMID: 26118714.